Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024591 (malignant hyperthermia)
 2,353 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

It is reported that ropivacaine, a new amide-linked local anesthetic, can be used safely in patients susceptible to malignant hyperthermia. We report a case of the use of epidural ropivacaine for a gravida with disposition for malignant hyperthermia. A 33-year-old female patient, 11 weeks and 2 days pregnant, was admitted for torsion of the right ovarian cyst. Five years before, she had been prepared for operation for uterine myoma. After premedication with atropine 0.5 mg and hydroxyzine 50 mg i.m. her body temperature increased to 39.0 degrees C, and the operation was postponed. By muscle biopsy she was diagnosed susceptible to malignant hyperthermia. Two months thereafter, the operation for uterine myoma was performed under epidural lidocaine and intravenous propofol anesthesia. Three years ago, she had cesarean section under epidural anesthesia using mepivacaine. This time, the epidural catheter was inserted at L 3-4 interspace, and 10 ml of 1.0% ropivacaine was administrated. After fifteen minutes analgesia was obtained to T 10-L 2. Forty minutes later the operation was performed and the patient was safely anesthetized by ropivacaine. Later at 37 weeks and 3 days pregnancy, cesarean section was performed with epidural ropivacaine.
 ...
PMID:[The use of epidural ropivacaine for a gravida with disposition for malignant hyperthermia]. 1507 78

The importance of early identification and management of the high-risk obstetric patient is emphasised in the Confidential Enquiry into Maternal and Child Health (CEMACH) report. High-risk patients who need anaesthetic input include those with airway problems, cardiorespiratory disease and rare genetic conditions, such as malignant hyperthermia and suxamethonium apnoea. Anaesthetic options for labour analgesia as well as anaesthesia for operative delivery will need to be discussed in detail with the patient if a delivery management plan is to be constructed. Input from other medical teams, such as cardiologists or haematologists, are often needed. Ultimately, these measures should reduce maternal morbidity and mortality.
 ...
PMID:The preoperative assessment of obstetric patients. 2004 59

Several high-profile examples of adverse outcomes from medications used in the perioperative setting are well known (e.g., malignant hyperthermia, prolonged apnea, respiratory depression, inadequate analgesia), leading to an increased understanding of genetic susceptibilities underlying these risks. Pharmacogenomic information is increasingly being utilized in certain areas of medicine. Despite this, routine preoperative genetic screening to inform medication risk is not yet standard practice. In this review, we assess the current readiness of pharmacogenomic information for clinical consideration for several common perioperative medications, including description of key pharmacogenes, pharmacokinetic implications and potential clinical outcomes. The goal is to highlight medications for which emerging or considerable pharmacogenomic information exists and identify areas for future potential research.
 ...
PMID:Pharmacogenomic considerations for medications in the perioperative setting. 3141 57


<< Previous 1 2